Xingsai Bio develops single-cell analysis instruments and supporting reagents and consumables. It offers an integrated “single-cell Raman imaging – sorting – sequencing – culture” solution. The company’s products and workflows target clinical precision medicine, human and environmental microbiomes, bioresource mining, cell-factory screening, industrial process monitoring, and biosafety. A recent corporate registration change shows a new shareholder entry for Maotai Sci‑Tech Innovation Fund holding 2.2222% of shares. The article does not disclose revenue, user metrics, or other financial details. Xingsai Biotech is a developer of single-cell analysis instruments and accompanying reagents and consumables. The company provides an integrated “single-cell Raman imaging–sorting–sequencing–culture” solution. Its platform is positioned to serve clinical precision medicine, human and environmental microbiome research, bioprospecting, cell-factory screening, industrial process monitoring, and biosafety. Recently the company completed a nearly ¥100 million Series A financing. Proceeds from the round will support expansion of the company’s industrial layout and accelerate R&D on its “Raman Group” industrial project and microfluidic technologies. The company also plans to strengthen brand building and to open international markets.

Total raised

$14M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2023